PMID- 20800881
OWN - NLM
STAT- MEDLINE
DCOM- 20101213
LR  - 20220330
IS  - 1527-9995 (Electronic)
IS  - 0090-4295 (Linking)
VI  - 76
IP  - 5
DP  - 2010 Nov
TI  - TMPRSS2-ERG gene fusion and clinicopathologic characteristics of Korean prostate 
      cancer patients.
PG  - 1268.e7-13
LID - 10.1016/j.urology.2010.06.010 [doi]
AB  - OBJECTIVES: To survey the status of TMPRSS2-ERG fusion in Korean prostate cancer 
      patients, we assessed the differences in clinicopathologic characteristics and 
      biochemical recurrence according to TMPRSS2-ERG fusion status. METHODS: The 
      incidence of the TMPRSS2-ERG fusion gene was evaluated via fluorescence in situ 
      hybridization (FISH) using ERG break-apart probes in 254 prostate cancer tissues 
      resected by radical prostatectomy, and analyses of clinicopathologic parameters 
      and biochemical recurrence were conducted. RESULTS: The fusion rate of the 
      TMPRSS2-ERG gene was 20.9% (53/254). TMPRSS2-ERG gene fusion was identified more 
      frequently in patients with low Gleason grade (primary Gleason pattern </= 3 or sum 
      of Gleason score </= 7, P = .015 and .027). Patients with large cribriform glands 
      in Gleason pattern 4 harbored a rare TMPRSS2-ERG fusion gene compared with 
      patients without large cribriform glands (P = .027). The incidence of biochemical 
      recurrence did not differ according to TMPRSS2-ERG fusion gene status (P = .598). 
      CONCLUSIONS: ERG gene aberration did not correlate with biochemical recurrence of 
      prostate cancers in Korean patients. Lower Gleason grade demonstrated higher 
      rates of TMPRSS2-ERG fusion compared with high-grade tumors, including those 
      demonstrating a large cribriform glands pattern. Prostate cancer with large 
      cribriform glands revealed rare TMPRSS2-ERG gene fusion.
CI  - Copyright (c) 2010 Elsevier Inc. All rights reserved.
FAU - Lee, Kyoungbun
AU  - Lee K
AD  - Department of Pathology, Seoul National University College of Medicine, Seoul, 
      Korea.
FAU - Chae, Ji Youn
AU  - Chae JY
FAU - Kwak, Cheol
AU  - Kwak C
FAU - Ku, Ja Hyeon
AU  - Ku JH
FAU - Moon, Kyung Chul
AU  - Moon KC
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100830
PL  - United States
TA  - Urology
JT  - Urology
JID - 0366151
RN  - 0 (Oncogene Proteins, Fusion)
RN  - 0 (TMPRSS2-ERG fusion protein, human)
RN  - EC 3.4.21.77 (Prostate-Specific Antigen)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Gene Fusion
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Korea
MH  - Male
MH  - Middle Aged
MH  - Oncogene Proteins, Fusion/genetics/*metabolism
MH  - Prostate-Specific Antigen/blood
MH  - Prostatic Neoplasms/blood/*genetics/*pathology
MH  - Protein Array Analysis
EDAT- 2010/08/31 06:00
MHDA- 2010/12/14 06:00
CRDT- 2010/08/31 06:00
PHST- 2009/11/17 00:00 [received]
PHST- 2010/05/19 00:00 [revised]
PHST- 2010/06/04 00:00 [accepted]
PHST- 2010/08/31 06:00 [entrez]
PHST- 2010/08/31 06:00 [pubmed]
PHST- 2010/12/14 06:00 [medline]
AID - S0090-4295(10)00797-1 [pii]
AID - 10.1016/j.urology.2010.06.010 [doi]
PST - ppublish
SO  - Urology. 2010 Nov;76(5):1268.e7-13. doi: 10.1016/j.urology.2010.06.010. Epub 2010 
      Aug 30.